| Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group. | |
| | |
MedLine Citation:
|
PMID: 15890569 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: Erb-1 (epidermal growth factor receptor, EGFR) and Erb-2 (Her-2) are two of the best characterized members in the EGFR pathway. In many tumor types, overexpression of these proteins is associated with enhanced malignant potential. Our objective in this study was to investigate the clinical relevance of EGFR and Her-2 expression in bladder cancer cases from four prospective Radiation Therapy Oncology Group (RTOG) bladder preservation trials using cisplatin-containing chemoradiation (RTOG 8802, 8903, 9506, and 9706). METHODS AND MATERIALS: Tumors from 73 cases from patients with muscle-invading T2-T4a bladder cancers had slides interpretable for EGFR staining; 55 cases had slides interpretable for Her-2 staining. Additionally, the respective prognostic values of p53, pRB, and p16 immunostaining were concomitantly examined. Staining and interpretation of staining were done in a blinded manner, without knowledge of clinical outcome. Staining was judged as positive or negative. Subsequently, staining was correlated with clinical outcome. RESULTS: On univariate analysis, EGFR positivity was significantly associated with improved overall survival (p = 0.044); disease-specific survival (DSS) (p = 0.042); and DSS with intact bladder (p = 0.021). There was also a trend for association between EGFR expression and reduced frequency of distant metastasis (p = 0.06). On multivariate analysis adding tumor stage, tumor grade, whether a visibly complete transurethral resection of bladder tumor (TURBT) was done or not, and patient age to the model, EGFR positivity was significantly associated with improved DSS. On univariate analysis, Her-2 positivity was significantly associated with reduced complete response (CR) rates (50% vs. 81%, p = 0.026) after chemoradiation which remained significant on multivariate analysis. The other markers examined in this study were not found to have any prognostic value in this setting. CONCLUSION: Epidermal growth factor receptor expression appears to correlate significantly with improved outcome in bladder cancer, whereas Her-2 expression is significantly associated only with reduced CR rates after chemoradiation. Further investigations are warranted into how EGFR family members regulate response to chemoradiation in bladder cancer and their potential therapeutic implications. |
| | |
Authors:
|
Arnab Chakravarti; Kathryn Winter; Chin-Lee Wu; Donald Kaufman; Elizabeth Hammond; Matthew Parliament; William Tester; Michael Hagan; David Grignon; Niall Heney; Alan Pollack; Howard Sandler; William Shipley |
Related Documents
:
|
22611969 - Malignant lymphoma of the vagina successfully treated with rituximab, adryamicin, cyclo... 3569329 - Primary tumor receptorial status and axillary metastases: their prognostic significance. 17429139 - Comparing the prognostic value of pten and akt expression with the mitotic activity ind... 22535619 - Increased suppressor of cytokine signaling-3 expression predicts mucosal relapse in ulc... 18650259 - Comparison of her-2 and hormone receptor expression in primary breast cancers and async... 18355939 - Egfr, ttf-1 and mdm2 expression in stage iii non-small cell lung cancer: a positive ass... 19615859 - Prognostic value of ki67 from clinically and histologically 'normal' distant mucosa in ... 12218569 - Micropapillary and cribriform patterns in ovarian serous tumors of low malignant potent... 19797519 - How i treat acute promyelocytic leukemia. |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S. |
Journal Detail:
|
Title: International journal of radiation oncology, biology, physics Volume: 62 ISSN: 0360-3016 ISO Abbreviation: Int. J. Radiat. Oncol. Biol. Phys. Publication Date: 2005 Jun |
Date Detail:
|
Created Date: 2005-05-13 Completed Date: 2005-06-27 Revised Date: 2009-11-19 |
Medline Journal Info:
|
Nlm Unique ID: 7603616 Medline TA: Int J Radiat Oncol Biol Phys Country: United States |
Other Details:
|
Languages: eng Pagination: 309-17 Citation Subset: IM |
Affiliation:
|
Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA. achakravarti@partners.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Analysis of Variance Antineoplastic Agents / therapeutic use Cisplatin / therapeutic use Combined Modality Therapy Cyclin-Dependent Kinase Inhibitor p16 / metabolism Female Humans Male Middle Aged Neoplasm Invasiveness Prognosis Receptor, Epidermal Growth Factor / metabolism* Receptor, erbB-2 / metabolism* Retinoblastoma Protein / metabolism Tumor Suppressor Protein p53 / metabolism Urinary Bladder Neoplasms / drug therapy, metabolism*, pathology, radiotherapy |
| Grant Support | |
ID/Acronym/Agency:
|
U10 CA21661/CA/NCI NIH HHS; U10 CA32115/CA/NCI NIH HHS; U10 CA37422/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Cyclin-Dependent Kinase Inhibitor p16; 0/Retinoblastoma Protein; 0/Tumor Suppressor Protein p53; 15663-27-1/Cisplatin; EC 2.7.10.1/Receptor, Epidermal Growth Factor; EC 2.7.10.1/Receptor, erbB-2 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Maintenance of certification for radiation oncology.
Next Document: Immunohistochemically determined total epidermal growth factor receptor levels not of prognostic val...